Tesla And Biogen Lead The SPY Lower Tuesday
U.S. indices were trading lower Tuesday as investors await an outcome from this week's Fed meeting.
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 14)
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $331
Truist Securities analyst Robyn Karnauskas maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $305 to $331.
10 Biggest Price Target Changes For Monday
Needham raised OrthoPediatrics Corp. (NASDAQ: KIDS) price target from $70 to $77. Vertex Pharmaceuticals shares rose 0.2% to close at $63.51 on Friday.
SVB Leerink Maintains Market Perform on Vertex Pharmaceuticals, Lowers Price Target to $200
SVB Leerink analyst Geoffrey Porges maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Market Perform and lowers the price target from $250 to $200.
64 Biggest Movers From Friday
Gainers
Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share.
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves.
Cathie Wood, Bullish On SpaceX Partner Velo3D, Buys More SPFR Shares, Adds Vertex On Dip
Cathie Wood-led Ark Investment Management on Friday bought 25,000 shares, estimated to be worth about $250,000, in Jaws Spitfire Acquisition Corp (NYSE: SPFR), the blank-check firm that is set to take 3D printing company Velo3D public.